Europe Actinic Keratosis Treatment Market Size, Share & Industry Trends Analysis Report By Drug Class, By Therapy (Surgery, Topical and Photodynamic Therapy), By End-use (Hospitals, Private Clinics, Homecare and Others), By Country and Growth Forecast, 20

Europe Actinic Keratosis Treatment Market Size, Share & Industry Trends Analysis Report By Drug Class, By Therapy (Surgery, Topical and Photodynamic Therapy), By End-use (Hospitals, Private Clinics, Homecare and Others), By Country and Growth Forecast, 2022 - 2028

The Europe Actinic Keratosis Treatment Market would witness market growth of 4.1% CAGR during the forecast period (2022-2028).

A multitude of factors is taken into account when developing a treatment strategy for AK. These include characteristics and symptoms of AK, the patient's expectations, and the availability of treatments, the patient's capacity to adhere to treatment regimens, the tolerability of side effects, and the cost of treatments.

When lesions are many, bleeding, painful, and/or expanding quickly in size, it is a sign of urgency. Utilizing specialized tools to scrape away and burn (electrodessicate) the AK base is known as electrodesication and curettage. This procedure is repeated multiple times to get rid of all the AK and create clear margins. There are several possible topical alternatives like drugs and topically applicable creams or gels.

Applying a lotion or gel to the exposed lesions is known as a topical treatment. If there are multiple AKs in one region, this strategy might be employed. The drug causes a skin reaction that kills the AKs after being applied for a predetermined period of time. Topical medications typically cause the skin to become red, although they are quite powerful. Several research studies on less abrasive topical therapies for actinic keratosis are being conducted as well.

The expansion of AK treatments in this region is fueled by the rising number of actinic keratosis instances that have been documented and rising medical tourism. Due to the high incidence of actinic keratosis and the rising popularity of minimally invasive procedures, the demand has significantly grown in the United Kingdom. The affordable actinic keratosis treatment as well as advantageous Medicaid and Medicare reimbursements also impact the preference for AK treatment.

The Germany market dominated the Europe Actinic Keratosis Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $527.3 Million by 2028.The UK market is experiencing a CAGR of 3.3% during (2022 - 2028). Additionally, The France market would experience a CAGR of 4.9% during (2022 - 2028).

Based on Drug Class, the market is segmented into Nucleoside Metabolic Inhibitor, NSAIDs, Immune Response Modifiers, Photoenhancers and Others. Based on Therapy, the market is segmented into Surgery, Topical and Photodynamic Therapy. Based on End-use, the market is segmented into Hospitals, Private Clinics, Homecare and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Almirall, S.A, LEO Pharma A/S, Biofrontera AG, Sun Pharmaceuticals Industries Ltd., 3M Company, Bausch Health Companies, Inc., Novartis AG, Viatris, Inc., and Galderma S.A.

Scope of the Study

Market Segments covered in the Report:

By Drug Class

  • Nucleoside Metabolic Inhibitor
  • NSAIDs
  • Immune Response Modifiers
  • Photoenhancers
  • Others
By Therapy
  • Surgery
  • Topical
  • Photodynamic Therapy
By End-use
  • Hospitals
  • Private Clinics
  • Homecare
  • Others
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
Companies Profiled
  • Almirall, S.A
  • LEO Pharma A/S
  • Biofrontera AG
  • Sun Pharmaceuticals Industries Ltd.
  • 3M Company
  • Bausch Health Companies, Inc.
  • Novartis AG
  • Viatris, Inc.
  • Galderma S.A.
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Actinic Keratosis Treatment Market, by Drug Class
1.4.2 Europe Actinic Keratosis Treatment Market, by Therapy
1.4.3 Europe Actinic Keratosis Treatment Market, by End-use
1.4.4 Europe Actinic Keratosis Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Actinic Keratosis Treatment Market by Drug Class
3.1 Europe Nucleoside Metabolic Inhibitor Market by Country
3.2 Europe NSAIDs Market by Country
3.3 Europe Immune Response Modifiers Market by Country
3.4 Europe Photoenhancers Market by Country
3.5 Europe Others Market by Country
Chapter 4. Europe Actinic Keratosis Treatment Market by Therapy
4.1 Europe Surgery Market by Country
4.2 Europe Topical Market by Country
4.3 Europe Photodynamic Therapy Market by Country
Chapter 5. Europe Actinic Keratosis Treatment Market by End-use
5.1 Europe Hospitals Market by Country
5.2 Europe Private Clinics Market by Country
5.3 Europe Homecare Market by Country
5.4 Europe Others Market by Country
Chapter 6. Europe Actinic Keratosis Treatment Market by Country
6.1 Germany Actinic Keratosis Treatment Market
6.1.1 Germany Actinic Keratosis Treatment Market by Drug Class
6.1.2 Germany Actinic Keratosis Treatment Market by Therapy
6.1.3 Germany Actinic Keratosis Treatment Market by End-use
6.2 UK Actinic Keratosis Treatment Market
6.2.1 UK Actinic Keratosis Treatment Market by Drug Class
6.2.2 UK Actinic Keratosis Treatment Market by Therapy
6.2.3 UK Actinic Keratosis Treatment Market by End-use
6.3 France Actinic Keratosis Treatment Market
6.3.1 France Actinic Keratosis Treatment Market by Drug Class
6.3.2 France Actinic Keratosis Treatment Market by Therapy
6.3.3 France Actinic Keratosis Treatment Market by End-use
6.4 Russia Actinic Keratosis Treatment Market
6.4.1 Russia Actinic Keratosis Treatment Market by Drug Class
6.4.2 Russia Actinic Keratosis Treatment Market by Therapy
6.4.3 Russia Actinic Keratosis Treatment Market by End-use
6.5 Spain Actinic Keratosis Treatment Market
6.5.1 Spain Actinic Keratosis Treatment Market by Drug Class
6.5.2 Spain Actinic Keratosis Treatment Market by Therapy
6.5.3 Spain Actinic Keratosis Treatment Market by End-use
6.6 Italy Actinic Keratosis Treatment Market
6.6.1 Italy Actinic Keratosis Treatment Market by Drug Class
6.6.2 Italy Actinic Keratosis Treatment Market by Therapy
6.6.3 Italy Actinic Keratosis Treatment Market by End-use
6.7 Rest of Europe Actinic Keratosis Treatment Market
6.7.1 Rest of Europe Actinic Keratosis Treatment Market by Drug Class
6.7.2 Rest of Europe Actinic Keratosis Treatment Market by Therapy
6.7.3 Rest of Europe Actinic Keratosis Treatment Market by End-use
Chapter 7. Company Profiles
7.1 Almirall, S.A
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Partnerships, Collaborations, and Agreements:
7.1.5.2 Product Launches and Product Expansions:
7.2 LEO Pharma A/S
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.3 Biofrontera AG
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Research & Development Expenses
7.4 Sun Pharmaceuticals Industries Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.5 3M Company
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 SWOT Analysis
7.6 Bausch Health Companies, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 Novartis AG
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.8 Viatris, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Galderma S.A.
7.9.1 Company Overview

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings